Emerging therapies in Friedreich’s Ataxia

References

• Campuzano V, Montermini L, Moltò MD, et al. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423–1427.
   PubMed Web of Science ®Google Scholar
• Bidichandani SI, Delatycki MB, Ataxia F, et al. eds. GeneReviews®. University of Washington, Seattle; 1993. [cited 2020 Apr 21]. http://www.ncbi.nlm.nih.gov/books/NBK1281/
   Google Scholar
• Filla A, De Michele G, Cavalcanti F, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet. 1996;59:554–560.
   PubMed Web of Science ®Google Scholar
• Klockgether T. Parkinsonism related disorders. 2007;13:S391–4. Ataxias Parkinsonism Relat Disord.
   PubMedGoogle Scholar
• Labuda M, Labuda D, Miranda C, et al. Unique origin and specific ethnic distribution of the Friedreich ataxia GAA expansion. Neurology. 2000;54:2322–2324.
   PubMed Web of Science ®Google Scholar
• Manto M, Marmolino D. Cerebellar ataxias. Curr Opin Neurol. 2009;22:419–429.
   PubMed Web of Science ®Google Scholar
• Dürr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med. 1996;335:1169–1175.
   PubMed Web of Science ®Google Scholar
• Bürk K, Schulz SR, Schulz JB. Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales. J Neurochem. 2013;126:118–124.
   PubMed Web of Science ®Google Scholar
• Raman SV, Phatak K, Hoyle JC, et al. Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome. Eur Heart J. 2011;32:561–567.
   PubMed Web of Science ®Google Scholar
• Weidemann F, Störk S, Liu D, et al. Cardiomyopathy of Friedreich ataxia. J Neurochem. 2013;126:88–93.
   PubMed Web of Science ®Google Scholar
• Koeppen AH, Ramirez RL, Becker AB, et al. The pathogenesis of cardiomyopathy in Friedreich ataxia. PLoS One. 2015;10(3):e0116396.
   PubMed Web of Science ®Google Scholar
• Payne RM, Wagner GR. Cardiomyopathy in Friedreich ataxia: clinical findings and research. J Child Neurol. 2012;27:1179–1186.
   PubMed Web of Science ®Google Scholar
• Clark E, Johnson J, Dong YN, et al. Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease. Neuronal Signal. 2018;2. DOI: 10.1042/NS20180060.
   PubMedGoogle Scholar
• Schulz JB, Dehmer T, Schöls L, et al. Oxidative stress in patients with Friedreich ataxia. Neurology. 2000;55:1719–1721.
   PubMed Web of Science ®Google Scholar
• Velasco-Sánchez D, Aracil A, Montero R, et al. Combined therapy with idebenone and deferiprone in patients with Friedreich’s ataxia. Cerebellum Lond Engl. 2011;10:1–8.
   PubMed Web of Science ®Google Scholar
• Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet. 1997;6:1771–1780.
   PubMed Web of Science ®Google Scholar
• Lagedrost SJ, Sutton MSJ, Cohen MS, et al. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J. 2011;161(639–45):e1.
   PubMedGoogle Scholar
• Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia.Heart 2002;87:346–349. [cited 2020 Apr 20].
   PubMed Web of Science ®Google Scholar
• Mariotti C, Solari A, Torta D, et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology. 2003;60:1676–1679.
   PubMed Web of Science ®Google Scholar
• Di Prospero NA, Baker A, Jeffries N, et al. Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007;6:878–886.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol. 2010;67:941–947.
   PubMed Web of Science ®Google Scholar
• Cook A, Boesch S, Heck S, et al. Patient‐reported outcomes in Friedreich’s ataxia after withdrawal from idebenone. Acta Neurol Scand. 2019:13088. [cited 2020 Apr 17]. Published June 1: http://onlinelibrary.wiley.com/doi/abs/10.1111/ane
   Web of Science ®Google Scholar
• Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev. 2010;16:183–188.
   PubMed Web of Science ®Google Scholar
• Clay A, Hearle P, Schadt K, et al. New developments in pharmacotherapy for Friedreich ataxia. Expert Opin Pharmacother. 2019;20:1855–1867.
   PubMed Web of Science ®Google Scholar
• Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann Neurol. 2001;49:590–596.
   PubMed Web of Science ®Google Scholar
• Hart PE, Lodi R, Rajagopalan B, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol. 2005;62:621–626.
   PubMedGoogle Scholar
• Cooper JM, Korlipara LVP, Hart PE, et al. Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol. 2008;15:1371–1379.
   PubMed Web of Science ®Google Scholar
• Martinelli D, Catteruccia M, Piemonte F, et al. EPI-743 reverses the progression of the pediatric mitochondrial disease—Genetically defined Leigh Syndrome. Mol Genet Metab. 2012;107:383–388.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Willi SM, Wilson RB, et al. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial. Mov Disord. 2012;27:1026–1033.
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of EPI-743 in patients with Friedreich’s ataxia - full text view - clinicalTrials.gov. 2012 [cited 2020 Apr 20]. https://clinicaltrials.gov/ct2/show/NCT01728064
   Google Scholar
• Harding AE. Friedreich’s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain J Neurol. 1981;104:589–620.
   Google Scholar
• Zesiewicz T, Salemi JL, Perlman S, et al. Double-blind, randomized and controlled trial of EPI-743 in Friedreich’s ataxia. Neurodegener Dis Manag. 2018;8:233–242.
   PubMed Web of Science ®Google Scholar
• Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–426.
   PubMed Web of Science ®Google Scholar
• Vomund S, Schäfer A, Parnham MJ, et al. Nrf2, the master regulator of anti-oxidative responses. Int J Mol Sci. 2017;18. DOI: 10.3390/ijms18122772.
   PubMed Web of Science ®Google Scholar
• Cullinan SB, Diehl JA. Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol. 2006;38:317–332.
   PubMed Web of Science ®Google Scholar
• Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2(Keap1) signaling in oxidative stress. Free Radic Biol Med. 2009;47:1304–1309.
   PubMed Web of Science ®Google Scholar
• Smith RE, Tran K, Smith CC, et al. The Role of the Nrf2/ARE antioxidant system in preventing cardiovascular diseases. Diseases. 2016;4. DOI:10.3390/diseases4040034.
   PubMedGoogle Scholar
• Shan Y, Schoenfeld RA, Hayashi G, et al. Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich’s ataxia YG8R mouse model. Antioxid Redox Signal. 2013;19:1481–1493.
   PubMed Web of Science ®Google Scholar
• Petrillo S, D’Amico J, La Rosa P, et al. Targeting NRF2 for the treatment of friedreich’s ataxia: A comparison among drugs. Int J Mol Sci. 2019;20(5211). DOI: 10.3390/ijms20205211
   Google Scholar
• RTA 408 Capsules in patients with friedreich’s ataxia - MOXIe - full text view - ClinicalTrials.gov. 2015 [cited 2020 Apr 20]. https://clinicaltrials.gov/ct2/show/NCT02255435
   Google Scholar
• Lynch DR, Farmer J, Hauser L, et al. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol. 2019;6:15–26.
   PubMed Web of Science ®Google Scholar
• Indelicato E, Bösch S. Emerging therapeutics for the treatment of Friedreich’s ataxia. Expert Opin Orphan Drugs. 2018;6:57–67.
   Web of Science ®Google Scholar
• Derosa G, Maffioli P. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol. 2012;5:272–281.
   PubMedGoogle Scholar
• Marmolino D, Acquaviva F, Pinelli M, et al. PPAR-gamma agonist Azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich’s ataxia therapy. Cerebellum Lond Engl. 2009;8:98–103.
   PubMed Web of Science ®Google Scholar
• Clinical A Study to evaluate the effect of MIN-102 on the progression of friedreich’s ataxia in male and female patients - no study results posted - ClinicalTrials.gov. 2019 [cited 2020 Jul 30]. https://clinicaltrials.gov/ct2/show/results/NCT03917225
   Google Scholar
• Dullens SPJ, Plat J, Mensink RP. Increasing apoA-I production as a target for CHD risk reduction. Nutr Metab Cardiovasc Dis NMCD. 2007;17:616–628.
   PubMed Web of Science ®Google Scholar
• Wang Q, Guo L, Strawser CJ, et al. Low apolipoprotein A-I levels in Friedreich’s ataxia and in frataxin-deficient cells: implications for therapy. PLoS One. 2018;13. DOI:10.1371/journal.pone.0192779.
   Web of Science ®Google Scholar
• Walker JL, Chamberlain S, Robinson N. Lipids and lipoproteins in Friedreich’s ataxia. J Neurol Neurosurg Psychiatry. 1980;43:111–117.
   PubMed Web of Science ®Google Scholar
• Baldo-Enzi G, Bernardo M, Vitale E, et al. Serum lipids, lipoprotein analysis and apoprotein A-I, A-II and B levels in Friedreich’s ataxia. Eur Neurol. 1990;30:132–137.
   PubMed Web of Science ®Google Scholar
• Wei T, Chen C, Hou J, et al. Nitric oxide induces oxidative stress and apoptosis in neuronal cells. Biochim Biophys Acta BBA - Mol Cell Res. 2000;1498:72–79.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brandrup-Wognsen G, Palmer MK, et al. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res. 2010;51:1546–1553.
   PubMed Web of Science ®Google Scholar
• Zesiewicz T, Heerinckx F, Jager RD, et al. Randomized, clinical trial of RT001: early signals of efficacy in Friedreich’s ataxia. Mov Disord. 2018;33:1000–1005.
   PubMed Web of Science ®Google Scholar
• A study to assess efficacy, long term safety and tolerability of RT001 in subjects with friedreich’s ataxia - full text view - ClinicalTrials.gov. 2019 [cited 2020 Apr 20]. https://clinicaltrials.gov/ct2/show/NCT04102501
   Google Scholar
• Gomes CM, Santos R. Neurodegeneration in Friedreich’s ataxia: from defective frataxin to oxidative stress. Oxid Med Cell Longev. 2013;487534. DOI:10.1155/2013/487534
   PubMed Web of Science ®Google Scholar
• Schmucker S, Martelli A, Colin F, et al. Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex. PLoS One. 2011;6. DOI:10.1371/journal.pone.0016199.
   Web of Science ®Google Scholar
• Xu W, Barrientos T, Andrews NC. Iron and copper in mitochondrial diseases. Cell Metab. 2013;17:319–328.
   PubMed Web of Science ®Google Scholar
• Pandolfo M, Hausmann L. Deferiprone for the treatment of Friedreich’s ataxia. J Neurochem. 2013;126:142–146.
   PubMed Web of Science ®Google Scholar
• Kretschmer BD, Kratzer U, Schmidt WJ. Riluzole, a glutamate release inhibitor, and motor behavior. Naunyn Schmiedebergs Arch Pharmacol. 1998;358:181–190.
   PubMed Web of Science ®Google Scholar
• Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: A randomized, double-blind, placebo-controlled pilot trial. Neurology. 2010;74:839–845.
   PubMed Web of Science ®Google Scholar
• Romano S, Coarelli G, Marcotulli C, et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14:985–991.
   PubMed Web of Science ®Google Scholar
• Punga T, Bühler M. Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation. EMBO Mol Med. 2010;2:120–129.
   PubMed Web of Science ®Google Scholar
• Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia. Nat Chem Biol. 2006;2:551–558.
   PubMed Web of Science ®Google Scholar
• Codazzi F, Hu A, Rai M, et al. Friedreich ataxia-induced pluripotent stem cell-derived neurons show a cellular phenotype that is corrected by a benzamide HDAC inhibitor. Hum Mol Genet. 2016;25:4847–4855.
   PubMed Web of Science ®Google Scholar
• Rai M, Soragni E, Jenssen K, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One. 2008;3. DOI:10.1371/journal.pone.0001958.
   Web of Science ®Google Scholar
• Soragni E, Miao W, Iudicello M, et al. Epigenetic therapy for Friedreich ataxia. Ann Neurol. 2014;76:489–508.
   PubMed Web of Science ®Google Scholar
• Effect of nicotinamide in friedreich’s ataxia - no study results posted - clinicalTrials.gov. 2012 [cited 2020 Apr 20]. https://clinicaltrials.gov/ct2/show/results/NCT01589809
   Google Scholar
• Libri V, Yandim C, Athanasopoulos S, et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich’s ataxia: an exploratory, open-label, dose-escalation study. Lancet Lond Engl. 2014;384:504–513.
   PubMed Web of Science ®Google Scholar
• Vyas PM, Tomamichel WJ, Pride PM, et al. A TAT–Frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich’s ataxia mouse model. Hum Mol Genet. 2012;21:1230–1247.
   PubMed Web of Science ®Google Scholar
• Puccio H, Anheim M, Tranchant C. Pathophysiogical and therapeutic progress in Friedreich ataxia. Rev Neurol (Paris). 2014;170:355–365.
   PubMed Web of Science ®Google Scholar
• Britti E, Delaspre F, Feldman A, et al. Frataxin-deficient neurons and mice models of Friedreich ataxia are improved by TAT-MTScs-FXN treatment. J Cell Mol Med. 2018;22:834–848.
   PubMed Web of Science ®Google Scholar
• Larimar Therapeutics, Inc. A phase 1 single ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous CTI-1601 versus placebo in subjects with Friedreich’s Ataxia. clinicaltrials.gov; 2019 [cited 2020 Jul 30]. https://clinicaltrials.gov/ct2/show/NCT04176991
   Google Scholar
• Tomassini B, Arcuri G, Fortuni S, et al. Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model. Hum Mol Genet. 2012;21:2855–2861.
   PubMed Web of Science ®Google Scholar
• Seyer L, Greeley N, Foerster D, et al. Open-label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurol Scand. 2015;132:7–15.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Hauser L, McCormick A, et al. Randomized, double-blind, placebo-controlled study of interferon-γ 1b in Friedreich Ataxia. Ann Clin Transl Neurol. 2019;6:546–553.
   PubMed Web of Science ®Google Scholar
• Boesch S, Indelicato E. Erythropoietin and Friedreich ataxia: time for a reappraisal? Front Neurosci. 2019;13. DOI:10.3389/fnins.2019.00386
   PubMed Web of Science ®Google Scholar
• Sturm B, Stupphann D, Kaun C, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest. 2005;35:711–717.
   PubMed Web of Science ®Google Scholar
• Boesch S, Sturm B, Hering S, et al. Neurological effects of recombinant human erythropoietin in Friedreich’s ataxia: a clinical pilot trial. Mov Disord Off J Mov Disord Soc. 2008;23:1940–1944.
   PubMed Web of Science ®Google Scholar
• Saccà F, Piro R, De Michele G, et al. Epoetin alfa increases frataxin production in Friedreich’s ataxia without affecting hematocrit. Mov Disord Off J Mov Disord Soc. 2011;26:739–742.
   PubMed Web of Science ®Google Scholar
• Nachbauer W, Wanschitz J, Steinkellner H, et al. Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia. Mov Disord. 2011;26:1935–1938.
   PubMed Web of Science ®Google Scholar
• Mariotti C, Nachbauer W, Panzeri M, et al. Erythropoietin in Friedreich ataxia. J Neurochem. 2013;126(Suppl 1):80–87.
   PubMedGoogle Scholar
• Mariotti C, Fancellu R, Caldarazzo S, et al. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov Disord Off J Mov Disord Soc. 2012;27:446–449.
   PubMed Web of Science ®Google Scholar
• Venturelli S, Berger A, Böcker A, et al. Resveratrol as a Pan-HDAC inhibitor alters the acetylation status of jistone proteins in human-derived hepatoblastoma cells. Gaetano C, ed. PLoS ONE. 2013;8. DOI:10.1371/journal.pone.0073097.
   PubMed Web of Science ®Google Scholar
• Yiu EM, Tai G, Peverill RE, et al. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. J Neurol. 2015;262:1344–1353.
   PubMed Web of Science ®Google Scholar
• Micronised Resveratrol as a Treatment for Friedreich Ataxia - Full Text View - ClinicalTrials.gov. 2019 [cited 2020 Apr 20]. https://clinicaltrials.gov/ct2/show/NCT03933163
   Google Scholar
• Alfedi G, Luffarelli R, Condò I, et al. Drug repositioning screening identifies etravirine as a potential therapeutic for friedreich’s ataxia. Mov Disord. 2019;34:323–334.
   PubMed Web of Science ®Google Scholar
• Palandri A, L’hôte D, Cohen-Tannoudji J, et al. Frataxin inactivation leads to steroid deficiency in flies and human ovarian cells. Hum Mol Genet. 2015;24:2615–2626.
   PubMed Web of Science ®Google Scholar
• Patel M, Schadt K, McCormick A, et al. Open-label pilot study of oral methylprednisolone for the treatment of patients with friedreich ataxia. Muscle Nerve. 2019;60:571–575.
   PubMedGoogle Scholar
• Perdomini M, Belbellaa B, Monassier L, et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich’s ataxia. Nat Med. 2014;20:542–547.
   PubMed Web of Science ®Google Scholar
• Piguet F, de Montigny C, Vaucamps N, et al. Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of friedreich ataxia. Mol Ther J Am Soc Gene Ther. 2018;26:1940–1952.
   PubMed Web of Science ®Google Scholar
• Li Y, Polak U, Bhalla AD, et al. Excision of expanded GAA repeats alleviates the molecular phenotype of friedreich’s ataxia. Mol Ther. 2015;23:1055–1065.
   PubMed Web of Science ®Google Scholar
• Zhang S, Napierala M, Napierala JS. Therapeutic prospects for friedreich’s ataxia. Trends Pharmacol Sci. 2019;40:229–233.
   PubMed Web of Science ®Google Scholar
• Li L, Matsui M, Corey DR. Activating frataxin expression by repeat-targeted nucleic acids. Nat Commun. 2016;7. DOI:10.1038/ncomms10606
   Web of Science ®Google Scholar
• Erwin GS, Grieshop MP, Ali A, et al. Synthetic transcription elongation factors license transcription across repressive chromatin. Science. 2017;358:1617–1622.
   PubMed Web of Science ®Google Scholar
• Pineda M, Arpa J, Montero R, et al. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol. 2008;12:470–475.
   PubMed Web of Science ®Google Scholar
• Buyse G, Mertens L, Di Salvo G, et al. Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring. Neurology. 2003;60:1679–1681.
   PubMed Web of Science ®Google Scholar
• Drinkard BE, Keyser RE, Paul SM, et al. Exercise capacity and idebenone intervention in children and adolescents with friedreich’s ataxia. Arch Phys Med Rehabil. 2010;91:1044–1050.
   PubMed Web of Science ®Google Scholar
• Rustin P, von Kleist-retzow JC, Chantrel-Groussard K, et al. Effect of idebenone on cardiomyopathy in Friedreich’s ataxia: a preliminary study. Lancet. 1999;354:477–479.
   PubMed Web of Science ®Google Scholar
• Sullivan KL, Freeman M, Shaw JD, et al. EPI-743 for friedreichs ataxia patients with point mutations (P5.388). [cited 2020 Apr 20]. Published 2016. .https://www.semanticscholar.org/paper/EPI-743-for-Friedreichs-Ataxia-Patients-with-Point-Sullivan-Freeman/88eb9ff8fb1f9907ba3c9b222de2543ea810626d.
   Google Scholar
• Boddaert N, Le Quan Sang KH, Rötig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood. 2007;110:401–408.
   PubMed Web of Science ®Google Scholar
• Boesch S, Sturm B, Hering S, et al. Friedreich’s ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol. 2007;62:521–524.
   PubMed Web of Science ®Google Scholar
• Boesch S, Nachbauer W, Mariotti C, et al. Safety and tolerability of carbamylated erythropoietin in Friedreich’s ataxia. Mov Disord. 2014;29:935–939.
   PubMed Web of Science ®Google Scholar
• Saccà F, Puorro G, Marsili A, et al. Long-term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia. Mov Disord. 2016;31:734–741.
   PubMed Web of Science ®Google Scholar